EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists

W Timothy Garvey iD, Cathy D Mahle, Trevor Bell iD, Robert F Kushner iD

Obesity Science & Practice · 2024-06 · 10 (3)

DOI: 10.1002/osp4.756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 04.05.2024. Verfasst von W Timothy Garvey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Sciences The University of Alabama at Birmingham Birmingham Alabama USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐obesity medications (AOMs) have historically had limited weight‐loss efficacy. However, newer glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)–based therapies seem to be more effective, including dual agonists of GLP‐1R and the glucagon receptor (GCGR) or glucose‐dependent insulinotropic polypeptide receptor.

Objective

To explore healthcare professionals' (HCPs) experience in obesity treatment and their understanding of agonists of GCGR, glucose‐dependent insulinotropic polypeptide (GIP) RA, and GLP‐1 RA.

Methods

This cross‐sectional online survey of HCPs prescribing AOMs was conducted in the United States in 2023 with a questionnaire designed to evaluate prescribing behavior and understanding of GCGR, GIP RA, and GLP‐1 RA.

Results

The 785 respondents (251 primary‐care physicians [PCPs], 263 endocrinologists, and 271 advanced practice providers [APPs]) reported 55% of their patients had obesity (body mass index ≥30 kg/m 2 or ≥27 with weight‐related complications) and recommended AOMs to 49% overall, significantly more endocrinologists (57% of patients, p < 0.0005) than PCPs (43%) or APPs (46%). The greatest barriers to treatment were medication cost/lack of insurance (mean 4.2 on 1–5 scale [no barrier–extreme barrier]), low patient engagement/adherence (3.3), and inadequate time/staff (3.1). Metformin was the type 2 diabetes (T2D) medication most commonly prescribed to treat obesity in T2D patients (92.5% of respondents). Most HCPs (65%) were very/extremely familiar with GLP‐1 RA, but only 30% with GIP RA and 16% with GCGR. Most HCPs expected dual GCGR/GLP‐1 RA to benefit many obesity‐related conditions; however, only a minority of HCPs perceived that they would benefit non‐cardiometabolic complications of obesity.

Conclusions

Among HCPs prescribing AOMs, gaps exist in the management of people living with obesity as

Schlagwörter

Stichwörter der Autor:innen

anti‐obesity agentsglucagonglucagon‐like peptide‐1glucose‐dependent insulinotropic polypeptidehealth care surveysobesity

Autor:innen und Institutionen

  • Department of Nutrition Sciences The University of Alabama at Birmingham Birmingham Alabama USA.
  • Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield Connecticut USA.
  • dQ&A San Francisco California USA.
  • Departments of Medicine (Endocrinology) and Medical Education Northwestern University Feinberg School of Medicine Chicago Illinois USA.

ORCID-Profile: W Timothy Garvey, Trevor Bell, Robert F Kushner

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Garvey, W. T., Mahle, C. D., Bell, T., & Kushner, R. F. (2024). Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists. Obesity Science & Practice, 10(3). https://doi.org/10.1002/osp4.756

Vancouver

Garvey WT, Mahle CD, Bell T, Kushner RF. Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists. Obesity Science & Practice. 2024;10(3). doi:10.1002/osp4.756

BibTeX
@article{Garvey2024,
  author = {Garvey, W Timothy and Mahle, Cathy D and Bell, Trevor and Kushner, Robert F},
  title = {Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists},
  journal = {Obesity Science & Practice},
  year = {2024},
  volume = {10},
  number = {3},
  doi = {10.1002/osp4.756}
}
Kostenlos starten →